C-Rad AB (publ)

CRAD-B · Nasdaq Stockholm · Healthcare

34.20SEK +1.8%last day

Price as of 2 October 2026

The price over the past year, with dividends: +6.5%

Performance

1 month

−2.3%

1 year

+6.5%

3 years, per year

+5.5%

5 years, per year

−9.7%

Largest fall, 3 years

−58.4%

Below the peak now

−48.6%

Volatility, 1 year

38.0%

Return with dividends reinvested.

Key figures

P/E

22.4

P/B

3.0

Dividend yield

0.3%

Return on equity

+13.6%

Net margin

+11.2%

Market value

115 m USD

Quality, value and trend

Where C-Rad stands against every Nordic stock today. 100 is best.

Quality84

Profitability and a sound balance sheet over time. Better than 84% of Nordic stocks.

Value37

The price measured against earnings, assets and cash flow. Better than 37% of Nordic stocks.

Trend64

The price development over the past year. Better than 64% of Nordic stocks.

Combined70

Quality, value and trend together. Better than 70% of Nordic stocks.

About C-Rad

C-Rad AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 98 employees.

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gat…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis